Nevertheless, starting from 2001, research unveiled that the RAS system also exhibits distinctive anti-inflammatory and CKD progression-inhibiting effects that are not solely tied to its blood pressure-lowering capabilities (138–141) In more recent years, as the understanding of the underlying mechanisms of DKD deepened and significant results from large-scale randomized controlled trials (RCTs) emerged, SGLT-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists have emerged as effective therapeutic options for addressing DKD. The gene discussed is SLC5A2; the disease is chronic kidney disease.